博瑞医药(688166)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

688166 博瑞医药

已收盘 07-30 15:00:00

{"stockData":{"symbol":"688166","market":"SH","secType":"STK","nameCN":"博瑞医药","latestPrice":100,"timestamp":1753858800000,"preClose":105.16,"halted":0,"volume":19908254,"delay":0,"changeRate":-0.0491,"floatShares":423000000,"shares":423000000,"eps":0.3266,"marketStatus":"已收盘","change":-5.16,"latestTime":"07-30 15:00:00","open":103.15,"high":108.15,"low":98,"amount":2027000000,"amplitude":0.0965,"askPrice":100,"askSize":149,"bidPrice":99.96,"bidSize":15,"shortable":0,"etf":0,"ttmEps":0.3266,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1753925400000},"marketStatusCode":5,"adr":0,"adjPreClose":105.16,"symbolType":"stock_kcb","openAndCloseTimeList":[[1753839000000,1753846200000],[1753851600000,1753858800000]],"highLimit":115.68,"lowLimit":94.64,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":422768244,"isCdr":false,"pbRate":17.43,"roa":"--","peRate":306.184936,"roe":"0.53%","epsLYR":0.45,"committee":0.089903,"marketValue":42277000000,"turnoverRate":0.0471,"status":1,"afterMarket":{"amount":0,"volume":0,"close":100,"buyVolume":0,"sellVolume":0,"time":1753860838019,"indexStatus":"已收盘 07-30 15:30:00","preClose":105.16},"floatMarketCap":42277000000},"requestUrl":"/m/hq/s/688166","defaultTab":"news","newsList":[{"id":"2555092629","title":"博瑞医药股价下跌5.19% 创新高后获利抛压叠加减持影响","url":"https://stock-news.laohu8.com/highlight/detail?id=2555092629","media":"智选洞察","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2555092629?lang=zh_cn&edition=full","pubTime":"2025-07-30 13:26","pubTimestamp":1753853179,"startTime":"0","endTime":"0","summary":"博瑞医药股价大幅下跌，最新价99.70元，跌幅5.19%。政策预期与资金博弈催生股价震荡近期博瑞医药股价波动与资金面多空博弈密切相关。此外，股价突破百元后触发获利盘抛压，叠加股东减持计划及监管警示函事件，进一步放大市场敏感度。技术壁垒与估值天平主导价值重塑博瑞医药在抗真菌原料药领域市占率超30%，外销收入占比达44.87%，原料药价格回暖与海外订单兑现效率或成业绩修复关键。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250730132628a6c90827&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250730132628a6c90827&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK0239","688166"],"gpt_icon":0},{"id":"2555088486","title":"超级真菌概念盘中拉升，联环药业涨6.02%","url":"https://stock-news.laohu8.com/highlight/detail?id=2555088486","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2555088486?lang=zh_cn&edition=full","pubTime":"2025-07-29 09:39","pubTimestamp":1753753192,"startTime":"0","endTime":"0","summary":"07月29日，超级真菌概念盘中拉升，截至09点39分，超级真菌概念整体指数上涨0.53%，报870.570点。从个股上来看，该概念的成分股中，联环药业涨6.02%，科伦药业、ST未名、诚意药业涨幅居前。从资金上来看，截止发稿，超级真菌概念主力净流入为-8545.53万，其中博瑞医药受到资金热捧，主力净流入1504.18万；拉长时间线来看，该板块近20日主力资金净流入-8.95亿。（以上内容为腾讯自选股基于公开消息，由程序或算法智能生成，仅作为用户看盘参考，不作为投资建议或交易依据。股市有风险，请谨慎决策。）","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250729093952a4689729&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250729093952a4689729&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK0239","688166","600513","603811"],"gpt_icon":0},{"id":"2555570206","title":"“反内卷”板块7月领涨两市，8月布局机构给出这三条主线","url":"https://stock-news.laohu8.com/highlight/detail?id=2555570206","media":"第一财经资讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2555570206?lang=zh_cn&edition=full","pubTime":"2025-07-29 07:50","pubTimestamp":1753746630,"startTime":"0","endTime":"0","summary":"7月政策暖风频吹，A股迎来阶段性反弹，沪指逼近3600点关口。本月以来，高层会议推动下，市场对“反内卷”的关注度极高，并演绎出一轮传统周期行业的估值修复行情。本轮“反内卷”政策层级高、频次高，月初至月中，钢铁、水泥等传统周期行业就已反复活跃调动市场人气。“反内卷”行情以外，生物医药在7月维持活跃表现。此外，生物医药板块7月涨幅前30名中，有23家来自科创板，亦反映资金博弈创新药企估值修复。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250728070307a6c4a46f&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250728070307a6c4a46f&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK0201","600111","BK0182","688202","BK0084","BK0188","688166","BK0055","688221","BK0241","BK0212","688425","600749","BK0101","BK0183","600010","600117","BK0000","BK0086","BK0012","BK0070","BK0216","BK0235","600392","399300","BK0102","BK0233","BK0033","BK0139","300436","BK0028","600326","BK0239","BK0196","BK0251","159982"],"gpt_icon":0},{"id":"2554675483","title":"博瑞生物医药（苏州）股份有限公司含卢比替定的药物组合物专利公布（医学或兽医学专利快讯）","url":"https://stock-news.laohu8.com/highlight/detail?id=2554675483","media":"DoNews","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2554675483?lang=zh_cn&edition=full","pubTime":"2025-07-25 15:15","pubTimestamp":1753427703,"startTime":"0","endTime":"0","summary":"天眼查App显示，2025年7月25日，《一种含卢比替定的药物组合物及其制备方法和应用》正式进入专利的公布阶段。申请人为博瑞生物医药（苏州）股份有限公司，该项医学或兽医学专利涉及癌症治疗相关药物制剂的技术场景。据专利信息显示，该药物组合物通过冻干工艺，使卢比替定在制剂中溶解完全，并在储存过程中保持pH值稳定，药物杂质含量低、稳定性强，显著优化了药物保存性能及应用前景。发明人为李佳晗、李会芳、董悦、黄仰青。该药物组合物的制备方法操作简便，生产成本低，有利于规模化生产，在治疗癌症等相关疾病中表现出重要的应用潜力。专利摘要显示，该技术为癌症治疗提供了新型药物制剂方案，并具有良好的产业化前景。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025072515182694ba008c&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025072515182694ba008c&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["399441","161726","688166","BK0239"],"gpt_icon":0},{"id":"2553275671","title":"超级真菌概念盘中拉升，达安基因涨停","url":"https://stock-news.laohu8.com/highlight/detail?id=2553275671","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2553275671?lang=zh_cn&edition=full","pubTime":"2025-07-24 13:14","pubTimestamp":1753334092,"startTime":"0","endTime":"0","summary":"07月24日，超级真菌概念盘中拉升，截至13点14分，超级真菌概念整体指数上涨2.03%，报858.980点。从个股上来看，该概念的成分股中，达安基因涨停，博瑞医药、尔康制药2只股涨幅超过5%。从资金上来看，截止发稿，超级真菌概念主力净流入为4781.39万，其中达安基因受到资金热捧，主力净流入9937.58万；拉长时间线来看，该板块近20日主力资金净流入-16.66亿。（以上内容为腾讯自选股基于公开消息，由程序或算法智能生成，仅作为用户看盘参考，不作为投资建议或交易依据。股市有风险，请谨慎决策。）","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250724131452a46081cd&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250724131452a46081cd&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["002030","BK0159","BK0028","688166","BK0042","BK0168","BK0239","BK0188","BK0122","BK0046"],"gpt_icon":0},{"id":"2553276970","title":"博瑞医药定增 董事长“两折”全部认购","url":"https://stock-news.laohu8.com/highlight/detail?id=2553276970","media":"经济观察网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2553276970?lang=zh_cn&edition=full","pubTime":"2025-07-24 12:57","pubTimestamp":1753333072,"startTime":"0","endTime":"0","summary":"根据预案，公司董事长、实际控制人之一袁建栋全额认购本次发行的股票。值得注意的是，此前博瑞医药及董事长袁建栋曾多次因信息披露，募集资金运用等问题被查处。近年来，在注册制改革的大方向下，监管部门对上市公司定增的审查常常涉及资金用途的正当性，以及定价是否公允等方面，博瑞医药董事长袁建栋这笔“两折”买股的定增，未来或将面临严格的审视。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250724135001a6bef565&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250724135001a6bef565&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["688166","BK0239"],"gpt_icon":0},{"id":"2553220496","title":"这只苏州股股价再创历史新高！","url":"https://stock-news.laohu8.com/highlight/detail?id=2553220496","media":"财富点点赢","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2553220496?lang=zh_cn&edition=full","pubTime":"2025-07-24 09:30","pubTimestamp":1753320614,"startTime":"0","endTime":"0","summary":"“昨天，A股三大指数涨跌不一，截至收盘，上证指数涨0.01%刷新年内高点，深证成指跌0.37%，创业板指跌0.01%。沪深两市成交额约18646亿元。值得注意的是，昨天，苏州股博瑞医药大涨2.88%，股价再创历史新高，总市值达401亿元。”自今年7月10日起，博瑞医药股价走势强劲，开启了连续10个交易日的上涨行情，累计涨幅高达68.65%。苏州证券业内人士分析称，博瑞医药股价创历史新高，是多重因素共振的结果。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250724104259a6bea97f&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250724104259a6bea97f&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["399001","688166","399300","BK0239","159982"],"gpt_icon":0},{"id":"2553607542","title":"超级真菌概念盘中拉升，东北制药涨8.90%","url":"https://stock-news.laohu8.com/highlight/detail?id=2553607542","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2553607542?lang=zh_cn&edition=full","pubTime":"2025-07-23 10:18","pubTimestamp":1753237085,"startTime":"0","endTime":"0","summary":"07月23日，超级真菌概念盘中拉升，截至10点18分，超级真菌概念整体指数上涨1.03%，报854.830点。从个股上来看，该概念的成分股中，东北制药涨8.90%，博瑞医药涨幅超过5%。从资金上来看，截止发稿，超级真菌概念主力净流入为726.71万，其中鲁抗医药受到资金热捧，主力净流入3020.95万；拉长时间线来看，该板块近20日主力资金净流入-15.20亿。（以上内容为腾讯自选股基于公开消息，由程序或算法智能生成，仅作为用户看盘参考，不作为投资建议或交易依据。股市有风险，请谨慎决策。）","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025072310180597b19490&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025072310180597b19490&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK0168","688166","BK0191","BK0188","600789","000597","BK0046","BK0239"],"gpt_icon":0},{"id":"2553271257","title":"减肥药板块集体走强","url":"https://stock-news.laohu8.com/highlight/detail?id=2553271257","media":"深圳商报","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2553271257?lang=zh_cn&edition=full","pubTime":"2025-07-23 00:44","pubTimestamp":1753202680,"startTime":"0","endTime":"0","summary":"7月22日，减肥药板块集体走强。截至收盘，丽珠集团上涨7.62%，博瑞医药上涨5.49%。这是WHO首次将减肥药物纳入官方推荐。据行业研究，GLP-1类药物凭借“降糖+减重”双效机制，已成为肥胖治疗首选，2030年全球市场规模或突破千亿美元。6月24日于美国举行的糖尿病协会第85届科学会议上，博瑞医药公布了其自主研发的GLP-1R/GIPR双靶点激动剂BGM0504的两项II期临床研究数据。研究表明，该药物在2型糖尿病患者中降糖疗效良好。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250723004444954d341b&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250723004444954d341b&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK0028","BK0114","688166","BK0077","BK0239","605116","600380","BK0046","BK0188","603087","688690"],"gpt_icon":0},{"id":"2553331532","title":"7月22日博瑞医药涨5.49%，富国优化增强债券A/B基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2553331532","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2553331532?lang=zh_cn&edition=full","pubTime":"2025-07-22 16:33","pubTimestamp":1753173236,"startTime":"0","endTime":"0","summary":"证券之星消息，7月22日博瑞医药涨5.49%创60日新高，收盘报92.1元，换手率3.78%，成交量15.96万手，成交额14.57亿元。重仓博瑞医药的前十大公募基金请见下表：该股最近90天内共有5家机构给出评级，买入评级4家，增持评级1家。根据2025基金半年报公募基金重仓股数据，重仓该股的公募基金共17家，其中持有数量最多的公募基金为富国基金的富国优化增强债券A/B。该公募基金现任基金经理为刘兴旺。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025072200026081.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688166","BK0239"],"gpt_icon":0},{"id":"2553831572","title":"仿制药一致性评价概念盘中拉升，丽珠集团涨停","url":"https://stock-news.laohu8.com/highlight/detail?id=2553831572","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2553831572?lang=zh_cn&edition=full","pubTime":"2025-07-22 10:05","pubTimestamp":1753149919,"startTime":"0","endTime":"0","summary":"07月22日，仿制药一致性评价概念盘中拉升，截至10点05分，仿制药一致性评价概念整体指数上涨1.04%，报1227.340点。从个股上来看，该概念的成分股中，丽珠集团涨停，辰欣药业、博瑞医药等6只股涨幅超过5%。从资金上来看，截止发稿，仿制药一致性评价概念主力净流入为7617.94万，其中恒瑞医药受到资金热捧，主力净流入8376.53万；拉长时间线来看，该板块近20日主力资金净流入-39.14亿。（以上内容为腾讯自选股基于公开消息，由程序或算法智能生成，仅作为用户看盘参考，不作为投资建议或交易依据。股市有风险，请谨慎决策。）","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025072210051997afc0dc&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025072210051997afc0dc&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["600276","01276","688166","603367"],"gpt_icon":0},{"id":"2553528865","title":"合成生物概念盘中拉升，健康元涨4.64%","url":"https://stock-news.laohu8.com/highlight/detail?id=2553528865","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2553528865?lang=zh_cn&edition=full","pubTime":"2025-07-22 09:40","pubTimestamp":1753148443,"startTime":"0","endTime":"0","summary":"07月22日，合成生物概念盘中拉升，截至09点40分，合成生物概念整体指数上涨0.51%，报1269.840点。从个股上来看，该概念的成分股中，健康元涨4.64%，凯莱英、博瑞医药、奥锐特涨幅居前。从资金上来看，截止发稿，合成生物概念主力净流入为-2.29亿，其中牧原股份受到资金热捧，主力净流入3276.57万；拉长时间线来看，该板块近20日主力资金净流入-77.14亿。（以上内容为腾讯自选股基于公开消息，由程序或算法智能生成，仅作为用户看盘参考，不作为投资建议或交易依据。股市有风险，请谨慎决策。）","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250722094043954c06ee&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250722094043954c06ee&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK0077","600380","06821","605116","688166","BK0028","BK0188","BK0046","BK0114","BK0239"],"gpt_icon":0},{"id":"2553283328","title":"超级真菌概念盘中拉升，博瑞医药涨3.29%","url":"https://stock-news.laohu8.com/highlight/detail?id=2553283328","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2553283328?lang=zh_cn&edition=full","pubTime":"2025-07-22 09:38","pubTimestamp":1753148330,"startTime":"0","endTime":"0","summary":"07月22日，超级真菌概念盘中拉升，截至09点38分，超级真菌概念整体指数上涨0.56%，报849.160点。从个股上来看，该概念的成分股中，博瑞医药涨3.29%，东北制药、华兰生物、亚泰集团涨幅居前。从资金上来看，截止发稿，超级真菌概念主力净流入为-2174.07万，其中博瑞医药受到资金热捧，主力净流入1410.18万；拉长时间线来看，该板块近20日主力资金净流入-9.93亿。（以上内容为腾讯自选股基于公开消息，由程序或算法智能生成，仅作为用户看盘参考，不作为投资建议或交易依据。股市有风险，请谨慎决策。）","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250722093850a45ae5d2&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250722093850a45ae5d2&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK0239","688166"],"gpt_icon":0},{"id":"2553281886","title":"超低价定增，减重大佬赢麻了","url":"https://stock-news.laohu8.com/highlight/detail?id=2553281886","media":"瞪羚社","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2553281886?lang=zh_cn&edition=full","pubTime":"2025-07-21 20:06","pubTimestamp":1753099560,"startTime":"0","endTime":"0","summary":"上方“瞪羚社”即刻关注并加入社群聚焦高成长公司，100000+投资菁英共同关注博瑞医药的大佬们赢麻了。7月19日博瑞医药发布了一系列公告，大部分均关乎公司定增发行二次修订稿。从规则来看，博瑞医药低价定增通过概率还是不小的。尽管患者基线有所差异，但从减重效果来看BGM0504可能是潜在双靶点双周制剂的潜在同类最佳。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250722124858a45b4b0c&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250722124858a45b4b0c&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK0239","688166"],"gpt_icon":0},{"id":"2552443184","title":"预喜率上升！超1500家公司业绩预告出炉，这些行业超预期","url":"https://stock-news.laohu8.com/highlight/detail?id=2552443184","media":"券商中国","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2552443184?lang=zh_cn&edition=full","pubTime":"2025-07-20 15:22","pubTimestamp":1752996135,"startTime":"0","endTime":"0","summary":"近期，大批上市公司业绩预告出炉，分析师也“马不停蹄”地跟踪、点评最新数据。A股公司上半年业绩预喜率较去年有所回升 Wind数据显示，截至目前，A股已有超1500家上市公司披露了2025年半年度业绩预告。从业绩增速来看，预告净利润同比增速下限超100%的公司超300家，超500%的有40余家。整体来看，近期上市公司发布的业绩预告是券商进行评级调整的主要原因，被上调评级的股票多是由于上半年业绩高增。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250720152215a6b51c12&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250720152215a6b51c12&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["159982","BK0226","688166","600882","399300","BK0077"],"gpt_icon":0},{"id":"2552446010","title":"博瑞医药拟向控股股东袁建栋发行2236万股 募资不超5亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2552446010","media":"财中社","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2552446010?lang=zh_cn&edition=full","pubTime":"2025-07-18 20:35","pubTimestamp":1752842132,"startTime":"0","endTime":"0","summary":"7月18日，博瑞医药发布公告，公司拟向特定对象袁建栋发行A股股票，发行数量不超过2236万股，募集资金总额不超过5亿元。袁建栋为公司控股股东及实际控制人之一，因此本次发行构成关联交易，但不构成重大资产重组。袁建栋全额认购本次发行的股票，并将其限售期由36个月延长至48个月，以支持公司的发展。2025年一季度，博瑞医药实现收入2.49亿元，归母净利润1296万元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250718203613954784b5&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250718203613954784b5&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["688166","BK0239"],"gpt_icon":0},{"id":"2552468031","title":"7月18日博瑞医药涨14.73%，鹏华上证科创板生物医药ETF基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2552468031","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2552468031?lang=zh_cn&edition=full","pubTime":"2025-07-18 16:19","pubTimestamp":1752826756,"startTime":"0","endTime":"0","summary":"证券之星消息，7月18日博瑞医药涨14.73%创60日新高，收盘报86.29元，换手率4.37%，成交量18.49万手，成交额14.99亿元。重仓博瑞医药的公募基金请见下表：该股最近90天内共有5家机构给出评级，买入评级4家，增持评级1家。根据2025基金半年报公募基金重仓股数据，重仓该股的公募基金共5家，其中持有数量最多的公募基金为鹏华基金的鹏华上证科创板生物医药ETF。鹏华上证科创板生物医药ETF目前规模为1.01亿元，最新净值1.1955，较上一交易日上涨3.13%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025071800025244.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["000001.SH","399300","BK0239","688166","512300","159982"],"gpt_icon":0},{"id":"2552468013","title":"博瑞医药涨14.73%，东吴证券二日前给出“买入”评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2552468013","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2552468013?lang=zh_cn&edition=full","pubTime":"2025-07-18 16:19","pubTimestamp":1752826748,"startTime":"0","endTime":"0","summary":"今日博瑞医药涨14.73%，收盘报86.29元。2025年7月16日，东吴证券研究员朱国广发布了对博瑞医药的研报《在研管线进展点评：BGM0504片IND申请获受理，稀缺双靶点口服多肽即将进入临床》，该研报对博瑞医药给出“买入”评级。考虑到公司管线逐步进入临床阶段，确定性增加，我们上调公司评级至“买入”评级。证券之星数据中心计算显示，对该股盈利预测较准的分析师团队为民生证券的王班、乔波耀。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025071800025241.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688166","601555"],"gpt_icon":0},{"id":"2552189455","title":"仿制药一致性评价概念盘中拉升，奥赛康涨6.36%","url":"https://stock-news.laohu8.com/highlight/detail?id=2552189455","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2552189455?lang=zh_cn&edition=full","pubTime":"2025-07-18 10:35","pubTimestamp":1752806141,"startTime":"0","endTime":"0","summary":"07月18日，仿制药一致性评价概念盘中拉升，截至10点35分，仿制药一致性评价概念整体指数上涨0.51%，报1184.820点。从个股上来看，该概念的成分股中，奥赛康涨6.36%，博瑞医药、千红制药2只股涨幅超过5%。从资金上来看，截止发稿，仿制药一致性评价概念主力净流入为-4.92亿，其中恒瑞医药受到资金热捧，主力净流入1.46亿；拉长时间线来看，该板块近20日主力资金净流入-23.05亿。（以上内容为腾讯自选股基于公开消息，由程序或算法智能生成，仅作为用户看盘参考，不作为投资建议或交易依据。股市有风险，请谨慎决策。）","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025071810354197aa8bc4&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025071810354197aa8bc4&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["600276","01276","688166"],"gpt_icon":0},{"id":"2552484738","title":"速递｜博瑞医药GLP-1双靶点激动剂首次启动海外 III 期临床","url":"https://stock-news.laohu8.com/highlight/detail?id=2552484738","media":"GLP1减重宝典","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2552484738?lang=zh_cn&edition=full","pubTime":"2025-07-17 18:44","pubTimestamp":1752749063,"startTime":"0","endTime":"0","summary":"整理 | GLP1减重宝典内容团队2025年7月14日，ClinicalTrials.gov 网站上显示，博瑞医药登记了一项用于治疗2型糖尿病的BGM0504 III期临床试验。BGM0504注射液是博瑞医药自主研发的GLP-1/GIP受体双重激动剂，能够同时激活GIP和GLP-1下游通路，从而改善血糖控制、减轻体重并治疗代谢功能障碍相关的脂肪性肝炎。目前进展根据Insight数据库，BGM0504已启动四项III期临床试验，其中三项在中国进行，一项在印度尼西亚进行。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250717212536a6aff313&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250717212536a6aff313&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["688166","BK0239"],"gpt_icon":0}],"profile":{"ret":0,"serverTime":1753891639029,"stockEarnings":[{"period":"1week","weight":0.1418},{"period":"1month","weight":0.9842},{"period":"3month","weight":1.1686},{"period":"6month","weight":2.4064},{"period":"1year","weight":2.9185},{"period":"ytd","weight":2.4877}],"compareEarnings":[{"period":"1week","weight":0.0078},{"period":"1month","weight":0.0542},{"period":"3month","weight":0.1008},{"period":"6month","weight":0.1105},{"period":"1year","weight":0.2482},{"period":"ytd","weight":0.077}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"博瑞生物医药(苏州)股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"10644人(较上一季度减少15.55%)","perCapita":"39718股","listingDate":"2019-11-08","address":"江苏省苏州市吴中区工业园区星湖街218号纳米科技园C25栋","registeredCapital":"42276万元","survey":"　　博瑞生物医药(苏州)股份有限公司的主营业务是医药中间体、原料药和制剂产品的研发、生产。公司的主要产品是抗病毒、抗真菌、免疫抑制、呼吸系统、抗肿瘤、恩替卡韦、奥司他韦、卡泊芬净、米卡芬净钠。公司先后获得“国家知识产权示范企业”、“国家知识产权优势企业”、“2017年度中国专利优秀奖”、“第十一届中国药学会科学技术奖一等奖”等多项荣誉。","listedPrice":12.71},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.34.4","shortVersion":"4.34.4","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"博瑞医药(688166)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供博瑞医药(688166)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"博瑞医药,688166,博瑞医药股票,博瑞医药股票老虎,博瑞医药股票老虎国际,博瑞医药行情,博瑞医药股票行情,博瑞医药股价,博瑞医药股市,博瑞医药股票价格,博瑞医药股票交易,博瑞医药股票购买,博瑞医药股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"博瑞医药(688166)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供博瑞医药(688166)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}